Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TA-99 is a murine monoclonal antibody of the IgG2a isotype that specifically targets tyrosinase-related protein 1 (TYRP1), also known as glycoprotein 75 (gp75). TYRP1 is a membrane-bound melanosomal enzyme involved in melanin biosynthesis and is highly expressed in melanocytes and melanoma cells. TA-99 is widely used as a gold-standard research tool in preclinical oncology, particularly in the B16F10 murine melanoma model, to evaluate the efficacy of immunotherapies, vaccines, and combination treatments. Its mechanism of action involves binding to TYRP1 on the surface of tumor cells, which triggers antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to tumor cell lysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TA-99.